A scientific statement from the American Heart Association was published in Circulation, with the purpose of providing a thorough review of available evidence on HIV-associated cardiovascular disease.
This article describes the populations at high risk for HIV infection and reports the results of a collaborative, multifaceted educational intervention designed to reduce the documented disparities related to HIV care and prevention.
Although the CDC recommends routine HIV screening for all people age 13-64 years, numerous barriers to HIV testing in healthcare settings have been identified, including lack of access and fear of stigma and discrimination.
People with HIV and cardiovascular disease have higher levels of the interleukin-1 receptor antagonist and soluble regulator sIL-1R1 up to 10 years before the first myocardial infarction.
Certain characteristics and HIV-related factors may help predict whether certain demographics of people with HIV will have an optimal response to reinforced hepatitis B virus vaccination.
Although incidence of histoplasma-associated immune reconstitution inflammatory syndrome is low, it still generates significant morbidity in people living with HIV.
The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to Pomalyst (pomalidomide; Celgene) for the treatment of patients with Kaposi sarcoma.
If the incidence rates were the same for black women as for white women, an estimated 93 percent of incident HIV infections among black women would not have occurred in 2016.
A 5-session couple-based intervention for men in community supervision programs and their female sexual partners significantly reduced reported risky sexual behaviors.
Analytical treatment interruption caused neither expansion of HIV reservoirs nor immunologic abnormalities after reinitiation of antiretroviral therapy.
